Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosutinib in Amyotrophic Lateral Sclerosis (ALS)
NCT04744532Phase 2Completed
- Sponsor
- Kyoto University
- Start
- Mar 2019
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bosutinib in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Kyoto University. Primary endpoints: Dose-limiting toxicity at 12 weeks, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised at 24 weeks and 5 more. Started Mar 2019; status: completed.
02
Drugs
bosutinib
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04744532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04744532.